Replying to @ATT
@ATT Very disappointed. Your store told my wife that her #Veteran designated driver’s license “doesn’t count” (your site says otherwise). You also told me that I don’t count because I’m a #JustAPharmacist, and not a nurse, physician, or PA... – at Tacoma, WA
1
And your Chat has told me 39 times now (every 3 minutes) that “We’re working hard to get you you.”
...and now you just closed the chat window w/o any response, or warning.
For those of you playing along at home, that was 2 HOURS.
What are you going to do to #MakeThisRight ? – at Tacoma, WA
No, not yet on formulary. #SGLT2TweetCHat – at Tacoma, WA
1
1
In preparing for this talk, I was floored by all the excellent resources available to HF patients. Thank you @HFSA @American_Heart @ACCinTouch @Novartis @medlineplus @nih_nhlbi @CDCgov
We can do better for our patients! – at Tacoma, WA
1
3
Today I was reminded just how intelligent #SGLT2 inhibitors are. They:
❕Only lower BG when it’s high
❕Don’t drop BP when it’s low
❕Are unlikely to cause hypovolemia
❕Only ⬇️ eGFR (initially) in T2DM, not in HFrEF w/o DM
❕Cause way less GU 🍄 infxn than previously thought – at Tacoma, WA
Credit where credit's due #HFSA2020 @JavedButler1 @JJheart_doc @MkosiborodMD @mrchrtfaildoc @Filippatos @SJGreene_md @FaiezZANNAD Milton Packer, Ileana Pina, Stefan Anker, Joao Pedro Ferreira, John McMurray
7
Def worth studying. Would love to see some prespecified subgroups for whoever designs future trials, maybe ischemic vs. not, T2DM vs. not, H/O HFrEF vs. not, H/O severe uncontrolled HTN vs. not... maybe some echo findings as well (conc. LVH? DD?)? And maybe a grade for self-care? – at Tacoma, WA
Does the benefit of HFrEF neurohormonal antagonists extend to patients in the mid-range? Very positive findings from trials but more data is needed @mvaduganathan in #ICON20 @SVCardio
1
1
Just when you thought endothelial dysfunction was bad enough already for its involvement in a host of common, prevalent, chronic diseases, here it comes again, swinging for the bleachers. – at Tacoma, WA
Back to the roots: Covid is an endothelial disease; sure, the lungs are affected, but CV causes are as important for the outcome, i.e. VTE due to TF , ischemia in all organs - inflammation as the final common pathway leading to endothelial dysfunction: red it, it's worth it!
I ❤️ @escardio, @drjohnm, and #FOAMed Seven Quick Thoughts on the New European AF Guidelines Teaser medscape.com/viewarticle/936… via @medscape – at Tacoma, WA
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
#COVID-19 as an endothelial disease. An insightful viewpoint from Peter Libby and @TomLuscher
academic.oup.com/eurheartj/a…
#cardiotwitter #CardioEd
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
Don’t stop those ACEI and ARBS in the #COVID19 patients. Just released from the @escardio meetings. @ACCinTouch #ACCCVT @accpcardprn @JGPharmD
#ESCCongress | BRACE CORONA: heart patients hospitalised with #COVID-19 can safely continue
taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
DIGOXIN is BACK! #RateAF trial. RCT: Bisoprolol vs Digoxin in permAF: similar HR reduction, BUT better daily functioning, better NYHA class/NT-proBNP and less clinical events. #Epeeps #cardiotwitter #ESCCongress
And here I thought I’d have to wait another 8 hours for this! Just waiting on FDA now... #SGLT2i #Empagliflozin for HFrEF. CKD. ASCVD. T2DM. Jeez.
Also, interesting trend for more benefit in pts on #ARNI
nejm.org/doi/pdf/10.1056/NEJ… – at Tacoma, WA
Cookbook Medicine Won't Cut It With New Drugs for HFrEF medscape.com/viewarticle/935… via @medscape – at Tacoma, WA
Maps on w/ clinical experience – at Tacoma, WA
Sacubitril/valsartan superior to valsartan alone for reduction of renal events in patients with #HFpEF and #CKD, study indicates. @CardiologyToday: https://nitter.cf/t.co/sWYL1ysGUl
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
Inpatient initiation of sacubitril-valsartan for patients with HFrEF may be associated with reduced hospitalizations, increased quality-adjusted life expectancy, and cost savings compared with no initiation or initiation after hospitalization ja.ma/2CkHpfg
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
Targeting #cardiovascular inflammation: next steps in clinical translation https://nitter.cf/t.co/Nm6ro3BlrS
@escardio #EHJ #ESC_Young #cardiotwitter @ehj_ed
Erik Kellison, PharmD, BCPS, BCACP, BCCP retweeted
Diagnose of #HFpEF is challenging. H2FPEF or HFA-PEFF scores might help to identify high risks in unexplained dyspnea. Great paper @mvaduganathan et al
Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community heartfailure.onlinejacc.org/…
Convo w/ #payor (P2P) this week: pt w/ CAD s/p CABG, controlled T2DM, HFrEF, hyper-TGs (179, 142), good LDL (48) on atorva 80, ASA 81, #Jardiance #Victoza metformin #Entresto Coreg, spiro (GDMT all @ #TargetDose)
Mutual agreement to add #Vascepa to further ⬇️ MACE incl. CV Death – at Tacoma, WA
1
1
This was after 2 P/A rejections:
1. “Use fibrates instead for hyper-TG” (it’s not FOR hyper-TG! Benefit independent of TG lowering, prescribed for CAD, detailed in my note)
2. “They don’t have CAD or CV risk factors” (why then do you think they underwent CABG as in my note?) – at Tacoma, WA
1



























